The Technical Analyst
Select Language :
Corvus Pharmaceuticals [CRVS]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Corvus Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Corvus Pharmaceuticals is listed at the  Exchange

1.70% $1.790

America/New_York / 27 mar 2024 @ 16:00


Corvus Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 87.78 mill
EPS: -0.560
P/E: -3.20
Earnings Date: May 05, 2024
SharesOutstanding: 49.04 mill
Avg Daily Volume: 0.216 mill
RATING 2024-03-27
B
Neutral
RATINGS
Rating CashFlow: Neutral
Return On Equity: Sell
Return On Asset: Sell
DE: Neutral
P/E: Sell
Price To Book: Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenuen/an/an/an/an/an/a
Gr.Profitn/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -3.20 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-0.54x
Company: PE -3.20 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$0.234
(-86.92%) $-1.556
Date: 2024-03-27
Expected Trading Range (DAY)

$ 1.626 - 1.954

( +/- 9.16%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-02-28 Arcara Jeffrey Buy 400 000 Stock Option (Right to Buy)
2024-02-02 Arcara Jeffrey Buy 0
2023-12-06 Miller Richard A Md Buy 500 000 Stock Option (Right to Buy)
2023-12-06 Lea Leiv Buy 200 000 Stock Option (Right to Buy)
2023-12-06 Jones William Benton Buy 200 000 Stock Option (Right to Buy)
INSIDER POWER
100.00
Last 97 transactions
Buy: 8 310 910 | Sell: 8 757 350

Forecast: 16:00 - $1.780

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $1.780
Forecast 2: 16:00 - $1.780
Forecast 3: 16:00 - $1.780
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $1.790 (1.70% )
Volume 0.160 mill
Avg. Vol. 0.216 mill
% of Avg. Vol 74.05 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Corvus Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Corvus Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Corvus Pharmaceuticals Inc

Last 10 Buy & Sell Signals For CRVS

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Profile picture for
            Corvus Pharmaceuticals Inc

CRVS

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.

Last 10 Buy Signals

Date Signal @
ETHXUSDMar 28 - 03:133 579.40
XAUTUSDMar 28 - 03:13$2 195.92
RADUSDMar 28 - 03:13$3.19
FLIPUSDMar 28 - 03:135.38
AGLDUSDMar 28 - 03:131.670
HNTUSDMar 28 - 03:10$5.95
JOEUSDMar 28 - 03:080.917
DYDXUSDMar 28 - 03:003.45
TIMEUSDMar 28 - 02:5833.66
TETUSDMar 28 - 02:5828.30

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.